Immunome's market cap is currently ―. The company's EPS TTM is $-5.382; its P/E ratio is -2.93; Immunome is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.68. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 3.83M	$ 3.56M	$ 4.26M	$ 2.36M	-
Gross Profit	$ 3.83M	$ 3.56M	$ 4.26M	$ 2.36M	-
EBIT	$ 66.97M	$ -4.63M	$ -5.77M	$ -4.47M	$ -7.79M
EBITDA	$ 66.76M	-	$ -5.62M	$ -4.32M	$ -7.55M
Net Income Common Stockholders	$ -92.63M	$ -4.34M	$ -5.56M	$ -4.27M	$ -7.79M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 138.14M	$ 90.64M	$ 38.42M	$ 44.42M	$ 20.32M
Total Assets	$ 148.54M	$ 93.16M	$ 41.44M	$ 48.11M	$ 24.05M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -138.14M	$ -90.64M	$ -38.42M	$ -44.42M	$ -20.32M
Total Liabilities	$ 28.66M	$ 87.08M	$ 32.10M	$ 34.25M	$ 24.05M
Stockholders Equity	$ 119.88M	$ 6.08M	$ 9.37M	$ 13.86M	$ 16.65M
Cash Flow	-
Free Cash Flow	$ -17.81M	-	$ -6.01M	$ 24.07M	$ -6.78M
Operating Cash Flow	$ -17.46M	$ -8.61M	$ -5.67M	$ 24.17M	$ -6.71M
Investing Cash Flow	$ -30.00M	$ -36.00K	$ -340.00K	$ -106.00K	$ -72.00K
Financing Cash Flow	$ 55.50M	$ 60.88M	-	$ 34.00K	-

Currency in USD

Immunome Earnings and Revenue History

Income Statement >

Immunome Debt to Assets

Balance Sheet >

Immunome Cash Flow

Cash Flow >

Immunome Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing